Healthcare >> Analyst Interviews >> March 20, 2020
Innovation Continues to Be Strong Despite Volatility in Biotech Sector
Yun Zhong is an Equity Research Analyst and Director of biotechnology research at Janney Montgomery Scott LLC. Dr. Zhong joined Janney in 2017 with over seven years of experience as an associate covering the biotechnology industry. He has experience in several therapeutic areas, including gene therapy, rare diseases, central nervous system disorders, infectious diseases, hepatobiliary disorders, among others. Earlier, Dr. Zhong spent three years at SunTrust Robinson Humphrey. Between 2011 and 2014, he worked as a biotechnology equity research associate at Cowen and Company. Dr. Zhong received his Ph.D. in neuroscience and molecular biology from Rockefeller University, and M.S. and B.S. degrees in biophysical engineering from Osaka University in Japan. He also was a postdoctoral fellow in neurology at New York’s Mount Sinai School of Medicine. Profile
Word count: 2,674
TWST: Could you explain what you cover?
Dr. Zhong: The biotech sector but, within the sector, specifically emerging to small-cap biotech names